Trigeminal Neuralgia Market 2017 Analysis and Forecast to 2021

Reasons to buy

– Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
– Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
– Find and recognize significant and varied types of therapeutics under development for Trigeminal Neuralgia (Central Nervous System).
– Classify potential new clients or partners in the target demographic.
– Develop tactical initiatives by understanding the focus areas of leading companies.
– Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
– Formulate corrective measures for pipeline projects by understanding Trigeminal Neuralgia (Central Nervous System) pipeline depth and focus of Indication therapeutics.
– Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
– Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents
List of Tables
List of Figures
Report Coverage
Trigeminal Neuralgia – Overview
Trigeminal Neuralgia – Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Trigeminal Neuralgia – Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Trigeminal Neuralgia – Companies Involved in Therapeutics Development
Allergan Plc
Biogen Inc
KPI Therapeutics Inc
Merz Pharma GmbH & Co KgaA
PixarBio Corp
Trigemina Inc
Trigeminal Neuralgia – Drug Profiles
(clonidine hydrochloride + naltrexone hydrochloride) – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Antisense Oligonucleotide to Inhibit SCN9A for Pain and Erythromelalgia – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
carbamazepine – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
incobotulinumtoxin A

Be the first to comment

Leave a Reply

Your email address will not be published.